The clinical efficacy and safety of TS-1 therapy were studied retrospectively in @entity1 with inoperable and recurrent @entity356 . The subjects were 45 @entity1 who were treated with TS-1 for more than 4 weeks at our center between May 1999 and July 2002. The objective overall response rate was 32% (14/44; 95% confidence interval, CI, 19-48). The response rate in the chemo-naive @entity1 was 44% (11/25; 95% CI, 24-65), and that in the @entity1 with previous chemotherapy was 16% (3/19; 95% CI, 3.4-40). Although doses or durations of TS-1 administration were reduced in 22 @entity1 (reduction group) due to adverse effects or poor performance status, they achieved a fairly high response rate of 38% (8/21). For primary lesions, the response rate was 30% (8/27). The prevalence of adverse reactions with a grade of 3 or 4 was 36%. However, the prevalence of each grade 3 or 4 adverse effect was relatively low, at 13% for @entity1398 , and around 5% for @entity448 , @entity390 , @entity391 , and @entity294 . The median administration period was 10 weeks (4-47 weeks) in all @entity1 and 11 weeks (6-47 weeks) in the reduction group. The relative dose intensity was 0.89 in all @entity1 and 0.81 in the reduction group. In @entity1 who were treated until August 2001, the @entity1349 ( @entity1349 ) was 13 months with 1-year and 2-year survival rates of 53% and 14%, respectively. These results were similar to those reported in the phase II study for the new drug approval. This study demonstrated the reproducible activity and safety of TS-1 in practice.

[Clinical study of TS-1 therapy for inoperable and recurrent XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['median survival time', 'MST']
@entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']
